Form 4: Enanta Pharmaceuticals Executive Reports Stock Transaction
Insider Transaction (Form 4)
Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc, reported a transaction in 1,467 shares of common stock on August 8, 2026.
Summary
- Tax/exercise-price withholding: disposed of 1,467 Common Stock at $13.34 ($19,570) on August 8, 2026; holds 23,787 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Scott T. Rottinghaus — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-08 | Tax/exercise-price withholding | Common Stock | 1,467 | $13 | $19.6K | 23,787 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-08 | Tax/exercise-price withholding (1,467 shares) |
Keywords
insider transaction, Form 4, ENTA, ENANTA PHARMACEUTICALS INC, neutral, Scott T. Rottinghaus
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.